司美格鲁肽降糖药中国销售首次下滑
Di Yi Cai Jing·2026-02-05 23:24
Group 1 - The core point of the article is that Novo Nordisk's stock price fell by 8.14% due to a decline in sales of its diabetes drug, Ozempic, in the Chinese market for the first time [2] - Sales of Ozempic in the Chinese market, including Hong Kong and Taiwan, decreased by 7% in 2025, amounting to approximately 5.4 billion Danish kroner (around 853 million USD) [2]